Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulacimstat in Post-MI LV Dysfunction
NCT02976467Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in left ventricular dysfunction comparing Fulacimstat with Placebo (2 arms). Primary endpoints: Change in left-ventricular ejection fraction at 6 months, Change in end diastolic volume index at 6 months and 1 more. Started Dec 2016; status: completed.
02
Drugs
fulacimstat
03
Conditions
left ventricular dysfunction
Beyond the preview
Go deeper on NCT02976467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02976467.